Get the Stockscreener App
5.00
1.63%
0.08
After Hours:
5.00
Codexis Inc stock is traded at $5.00, with a volume of 621.24K.
It is up +1.63% in the last 24 hours and down -11.19% over the past month.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
See More
Previous Close:
$4.92
Open:
$5.01
24h Volume:
621.24K
Relative Volume:
0.92
Market Cap:
$406.89M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-4.5045
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
+13.90%
1M Performance:
-11.19%
6M Performance:
+45.35%
1Y Performance:
+86.57%
1-Day Range:
$4.85
$5.07
1-Week Range:
$4.24
$5.07
52-Week Range:
$2.53
$6.08
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
5.00 | 406.89M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Codexis, Inc. (NASDAQ:CDXS) Sees Significant Increase in Short Interest - MarketBeat
Codexis expands board with new director Christos Richards - MSN
Tallon Kerry Patrick Purchases New Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Barclays PLC Purchases 70,255 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Barclays PLC Has $640,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis appoints new independent director By Investing.com - Investing.com Australia
Codexis expands board with new director Christos Richards By Investing.com - Investing.com Canada
Codexis, Inc. Appoints Christos Richards to Board of Directors -January 16, 2025 at 04:05 pm EST - Marketscreener.com
Codexis appoints new independent director - Investing.com India
Codexis Appoints Christos Richards to Board of Directors - TipRanks
Codexis Strengthens Board with Life Sciences Veteran Christos Richards, Expert in 450+ Executive Placements - StockTitan
Jane Street Group LLC Reduces Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (NASDAQ:CDXS) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Codexis (NASDAQ:CDXS) Stock Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Synthetic DNA Market Set to Witness Stunning Growth by 2024 Ti - openPR
Codexis Announces New Employment Inducement Grants - GlobeNewswire
Codexis Awards Strategic Equity Grants to New Employees Under 2024 Inducement Plan - StockTitan
Is There An Opportunity With Codexis, Inc.'s (NASDAQ:CDXS) 22% Undervaluation? - Yahoo Finance
Codexis sees $210,994 stock purchase by Opaleye management - Investing.com Nigeria
Geode Capital Management LLC Boosts Stake in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Caribou Biosciences Strengthens Leadership Team with Veteran Biotech CFO Sri Ryali - StockTitan
Codexis sees $210,994 stock purchase by Opaleye management By Investing.com - Investing.com South Africa
Codexis, Inc. (NASDAQ:CDXS) Short Interest Up 10.5% in December - MarketBeat
State Street Corp Acquires 41,480 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Stifel Financial Corp Lowers Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Stifel Financial Corp Has $530,000 Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
BNP Paribas Financial Markets Trims Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (NASDAQ:CDXS) Stock Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution - Investing.com India
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution By Investing.com - Investing.com South Africa
Codexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - Yahoo Finance
Is Codexis (NASDAQ:CDXS) Using Debt In A Risky Way? - Simply Wall St
Jacobs Levy Equity Management Inc. Decreases Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Awards Strategic Equity Package: 208K Shares in Options and RSUs for Key New Hires - StockTitan
Codexis stock soars to 52-week high, touches $4.92 By Investing.com - Investing.com Canada
Codexis stock soars to 52-week high, touches $4.92 - Investing.com India
Global Artificial Sweeteners Market to Observe Growth at a CAGR of ~4% by 2030 | DelveInsight - GlobeNewswire Inc.
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Fred Alger Management LLC - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Sees Large Decrease in Short Interest - MarketBeat
Cantor Fitzgerald Reaffirms “Overweight” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzymatic platform poised to shake up RNAi stock - Investing.com
Codexis (NASDAQ:CDXS) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
GSA Capital Partners LLP Grows Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):